Cystic fibrosis: Bench to bedside 2003

Canadian Respiratory Journal

Volumn 10, Issue 3, 2003, Pages 161-164

  Rubin, Bruce K ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CHLORIDE; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; CORTICOSTEROID; DORNASE ALFA; DURAMYCIN; IBUPROFEN; LEUKOCYTE ELASTASE; LIPOSOME; LUNG SURFACTANT EXTRACT; MACROLIDE; MUCOLYTIC AGENT; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; SODIUM; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS VECTOR; WATER;

ADENO ASSOCIATED VIRUS; BODY WEIGHT DISORDER; CANADA; CHLORIDE TRANSPORT; CONFERENCE PAPER; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GROWTH DISORDER; HAEMOPHILUS; HUMAN; IMMUNOMODULATION; LUNG TRANSPLANTATION; PANCREAS FUNCTION; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PSEUDOMONAS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; SODIUM TRANSPORT; STAPHYLOCOCCUS; TREATMENT OUTCOME; WATER TRANSPORT; WEIGHT GAIN;

EID: 0037838659     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/797054     Document Type: Conference Paper

References (39)

1. Tsui LC, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985;230:1054-7.
2. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-50.
3. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2001:5121-88.
4. Rubin BK. Emerging therapies for cystic fibrosis lung disease. Chest 1999;115:1120-6.
5. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med 2002;347:401-7.
6. Wang XJ, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-9.
7. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339:653-8.
8. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995;127:705-10.
9. Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-80.
10. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999;103:309-12.
11. Davis PB, Drumm M, Konstan MW. State of the art: Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-56.
12. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment. Pediatr Pulmonol 1996;21:153-8.
13. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
14. Ramsey BW, Dworkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
15. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996;42:186-91.
16. Konstan MW, Berger M. Infection and inflammation of the lung in cystic fibrosis. In: Davis PB, ed. Cystic Fibrosis. New York: Marcel Dekker, 1993:219-76.
17. Tomkiewicz RP, Kishioka C, Freeman J, Rubin BK. Chapter 34: DNA and actin filament ultrastructure in cystic fibrosis sputum. In: Baum G, ed. Cilia, Mucus, and Mucociliary Interactions. New York: Marcel Dekker, 1998:333-41.
18. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic fibrosis foundation prednisone trial group. J Pediatr 1995;126:515-23.
19. Nikolaizik WH, Schöni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996;128:271-4.
20. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-54.
21. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukaprotease inhibitor. J Clin Invest 1992;90:1296-1301.
22. Çulic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001;429:209-29.
23. Kudoh S, Uetake K, Hirayama M, Kyo E, Kimura H, Sugiyama Y. [Clinical effects of low-dose erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1987;25:632-42.
24. Jaffé A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-73.
25. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
26. Boucher RC. State of the art: Human airway ion transport. Am J Respir Crit Care Med 1994;150;271-81,581-93.
27. Rubin BK, Tomkiewicz RP, King M. Mucoactive agents: old and new. In: Wilmott RW, ed. The Pediatric Lung. Basel: Birkhäuser Publishing, 1997:155-79.
28. Girod S, Galabert C, Lecuire A, Zahm JM, Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr Pulmonol 1992;13:11-5.
29. Anzueto A, Jubran A, Char JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial. JAMA 1997;278:1426-31.
30. Griesenbach U, Ferrari S, Geddes DM, Alton EW. Gene therapy progress and prospects: Cystic fibrosis. Gene Ther 2002;9:1344-50.
31. Flotte TR, Carter BJ. In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis. Adv Pharmacol 1997;40:85-101.
32. Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002;13:1961-70.
33. Gill DR, Southern KW, Mofford KA, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:199-209.
34. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-92.
35. Brodsky JL. Chaperoning the maturation of the cystic fibrosis transmembrane conductance regulator. Am J Physiol Lung Cell Mol Physiol 2001;281:L39-42.
36. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002;6:119-26.
37. Suaud L, Li J, Jiang Q, Rubenstein RC, Kleyman TR. Genistein restores functional interactions between Delta F508-CFTR and ENaC in Xenopus oocytes. J Biol Chem 2002;277:8928-33.
38. Bennett LE, Keck BM, Hertz MI, Trulock EP, Taylor DO. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international registry for thoracic organ transplantation. Clin Transpl 2001;25-40.
39. Egan TM, Detterbeck FC, Mill MR, et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002;22:602-9.